Health
Key things to know about the Novavax vaccine
Novavax is a biotechnology company that specializes in the development of vaccines. During the pandemic, one of the most notable vaccine candidates developed by the company was its COVID-19 vaccine. Known as NVX-CoV2373 or simply the Novavax COVID-19 vaccine, it received regulatory approvals in various countries. However, the eligibility criteria for receiving the vaccine may vary from one country to another. Here are a few key facts about the vaccine: How was the Novavax COVID-19 vaccine developed? Novavax developed its COVID-19 vaccine to stimulate an immune response against the SARS-CoV-2 virus responsible for the pandemic. So, the NVX-CoV2373 vaccine is a protein subunit vaccine. It does not have a live or weakened virus, but rather, it uses a small piece of the virus’s spike protein to trigger an immune response. Here is how it was developed and tested: – Novavax conducted multiple phases of these clinical trials to assess the safety and efficacy of its COVID-19 vaccine. These trials took place in various countries, and the efficacy of the Novavax COVID-19 vaccine varied depending on the trial location and the prevalence of virus variants. Efficacy rates ranged from around 48.6% to over 90%, depending on the specific trial and the circulating variants.
Read More